Abstract Number: 782 • 2014 ACR/ARHP Annual Meeting
Temporal Artery Microbiome in Giant Cell Arteritis
Background/Purpose: Whether infectious agents play a part in giant cell arteritis (GCA) remains controversial. We have performed the first microbiome study of snap-frozen temporal arteries,…Abstract Number: 2667 • 2013 ACR/ARHP Annual Meeting
Fast-Track Pathway In Giant Cell Arteritis: A Cost-Effectivenss Analysis
Background/Purpose: With incidence of 2.2 per 10,000 patient years, it is estimated that 12,000 new cases of Giant Cell Arteritis (GCA) are diagnosed every…Abstract Number: 1861 • 2013 ACR/ARHP Annual Meeting
Neurotrophins Are Involved In Vascular Remodeling Of Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is a large-vessels vasculitis. Hhistopathological findings show cellular infiltrates, internal elastic lumina disruption and intimal hyperplasia leading to luminal stenosis.…Abstract Number: 1688 • 2013 ACR/ARHP Annual Meeting
Does The Treatment With Anti-Coagulants and Anti-Platelets Protect Giant Cell Arteritis Patients From Visual Manifestations?
Background/Purpose: Visual manifestations such as diplopia, amaurosis fugax or blindness occur in up to half of the giant cell arteritis (GCA) patients. Some studies have…Abstract Number: 1665 • 2013 ACR/ARHP Annual Meeting
B Cells Revisited In Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is a primary vasculitis affecting large to medium-sized arteries. Ample evidence suggests that dendritic cells, T cells and monocytes/macrophages contribute…Abstract Number: 1666 • 2013 ACR/ARHP Annual Meeting
Negative Temporal Artery Biopsies: Pathologic Findings Of Patients With Biopsy-Negative Giant Cell Arteritis Compared To Those Of Patients Without Arteritis
Background/Purpose: Temporal artery biopsy (TAB) showing transmural inflammation is considered the gold standard for the diagnosis of giant cell arteritis (GCA). A negative TAB does…Abstract Number: 1677 • 2013 ACR/ARHP Annual Meeting
May Giant Cell Arteritis Be Characterized By Different Clinical Entity and Long-Term Outcome?
Background/Purpose: Giant cell arteritis (GCA) represents the most common primary vasculitis of the elderly, that affect large and medium-sized arterial vessels. Growing data shown that…Abstract Number: 1678 • 2013 ACR/ARHP Annual Meeting
How Similar Are Extracranial Giant Cell Arteritis and Takayasu Arteritis?
Background/Purpose: The clinical and radiographic features of giant cell arteritis (GCA) with extracranial (large-vessel) involvement can be similar to those of Takayasu arteritis (TAK)…Abstract Number: 1664 • 2013 ACR/ARHP Annual Meeting
Lower Tissue Expression Of IL 6 In Patients With Giant Cell Arteritis Presenting With a Cranial Ischaemic Compication
Background/Purpose: Giant Cell Arteritis (GCA) is a granulomatous systemic vasculitis with a prediliction for the aorta and it’s extracranial branches. The majority of the morbidity…Abstract Number: 892 • 2013 ACR/ARHP Annual Meeting
The Functional PTPN22 Variant R620W Is Strongly Associated With Giant Cell Artetitis Predisposition
Background/Purpose: The PTPN22/CSK signaling represents one of the common susceptibility pathways in autoimmunity. Considering that the genetic basis of giant cell arteritis (GCA), an autoimmune…Abstract Number: 896 • 2013 ACR/ARHP Annual Meeting
Increased Rho Kinase (ROCK) Activity In Temporal Artery Biopsies From Patients With Giant Cell Arteritis (GCA)
Background/Purpose: ROCKs are implicated in the pathogenesis of many vascular diseases. ROCK activation is associated with Th17 differentiation and production of Th17-associated cytokines, IL-17 and…Abstract Number: 2354 • 2012 ACR/ARHP Annual Meeting
The Prevalence of Low Bone Mineral Density in Patients with New Onset Giant Cell Arteritis. Do They Get Appropriate Bone Protective Treatment?
Background/Purpose: Giant cell arteritis (GCA) is a common form of vasculitis mainly affecting individuals older than 50 years with a mean onset age of 69…Abstract Number: 2355 • 2012 ACR/ARHP Annual Meeting
Increase in Duration and Cumulative Dose of Glucocorticoid Therapy in Recent Decades: Observations From a Population-Based Cohort of Patients with Giant Cell Arteritis
Background/Purpose: Systemic glucocorticoid (GC) therapy is the first line treatment for giant cell arteritis (GCA). Patients with GCA are often counseled that therapy will be…Abstract Number: 2357 • 2012 ACR/ARHP Annual Meeting
Relapses in Patients with Giant-Cell Arteritis: Prevalence, Characteristics and Associated Clinical Findings in a Prospectively Followed Cohort of 106 Patients
Background/Purpose: In spite of the satisfactory initial response to glucocorticoid treatment, patients with giant cell arteritis (GCA) frequently experience relapses during follow-up. The objectives of…Abstract Number: 2359 • 2012 ACR/ARHP Annual Meeting
Outcome of Aortic Involvement in GIANT CELL Arteritis (GCA) After 1-Year Follow-up: Prospective Study in 35 Patients Using Computed Tompography Angiography (CTA)
Background/Purpose: 65% of patients with newly diagnosed, biopsy-proven GCA showed radiologic finding of aortitis using CTA in a prospective study of 40 patients. By segments,…
ACR Meeting Abstracts